An interventional study of SMS Reminders and SMS reminders + mailed reminder in Colorectal Cancer, sponsored by National Cancer Centre, Singapore. Not yet recruiting at 5 sites in Singapore. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by National Cancer Centre, Singapore · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Colorectal Neoplasms with a site in Singapore — 13 open to participants now, 20 under way, 5 of them phase 3. Colorectal Neoplasms · Singapore.
Among the 63 studies in Colorectal Neoplasms with a site in Singapore, this one has the largest planned enrollment of the 54 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, reaches primary completion later than 17 of the 19 other live ones, and was the 63rd registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →13 of the 63 studies in Colorectal Neoplasms with a site in Singapore are open now. Recruiting first, the newest first:
Singapore General Hospital · Sites in Singapore
Ages 21+
Bristol-Myers Squibb · Sites in Singapore, United States, Argentina and 22 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Singapore, United States, Canada and 4 more countries
Ages 18+
Alentis Therapeutics AG · Sites in Singapore, United States, France and 5 more countries
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 17 · Phase 3 17
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40,000 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 180 across the 54 interventional studies, 775 across the 8 observational. Of the 36 that completed or were terminated, 13 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 63 have an industry lead sponsor. The 10 most frequent:
National Cancer Centre, Singapore is the lead sponsor of 117 studies on the registry; 29 are open to participants now.
National Cancer Centre, Singapore has 7 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Colorectal Neoplasms with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04912765National Cancer Centre, SingaporeNeoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Colorectal Neoplasms with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal cancer (CRC) is the second most common cancer and the second leading cause of cancer-related mortality in Singapore. Although annual fecal immunochemical testing (FIT) and periodic colonoscopy are recommended for average-risk adults aged 50-75, only 44.9% of eligible individuals are up to date with CRC screening. Screening participation, adherence to repeat annual FIT, and completion of diagnostic colonoscopy after abnormal FIT results remain suboptimal. This study aims to identify the most effective and cost-effective strategy for increasing CRC screening participation and adherence.
CRC is the second most common cancer and cause of cancer-related mortality in Singapore. However, completion of CRC screenings remains suboptimal, with only 44.9% of eligible adults aged 50-74 years in Singapore up to date with CRC screening, far below the recommended 80% CRC screening completion rate set by the US Multi-Society Task Force on CRC. Singapore currently adopts a risk-stratified model for CRC screening, in which asymptomatic individuals without a family history of CRC are regarded as average-risk and are recommended annual fecal immunochemical test (FIT) or 5 to 10 yearly colonoscopies from 50 years old. However, these are usually recommended opportunistically by primary care providers during a routine healthcare visit. Among average-risk individuals, patients are more likely to participate in stool-based testing (34%-39%) than colonoscopy (24%-31%).
While FIT screening is cost-effective for health systems while reducing CRC mortality, the substantial screening gap underscores the need for interventions to increase FIT uptake. Numerous studies in other settings have compared the effectiveness of interventions such as mailed FIT, patient reminders, and patient navigation in improving screening uptake. Among these, mailed FIT outreach has emerged as a particularly effective strategy, reducing logistical barriers and enabling wider population coverage. Gupta et al. found that CRC screening participation was significantly higher for patients with mailed FIT (40.7%) compared to usual care (12.1%). A meta-analysis of randomized controlled trials (RCTs) by Ramal et al. found that patient navigation (RR, 1.58; 95% CI, 1.23-2.02) outperformed usual care in increasing CRC screening uptake. Meanwhile, a recent trial by Korostoff-Larsson et al. found that SMS reminders were associated with significantly improved FIT completion compared with usual telephone call reminders (58.9% vs 49.8%). The TEMPO trial by Robb et al. found that setting a 2-week deadline increased the FIT return rate compared with control (68.0% vs 63.2%). However, most of these studies compared single outreach interventions against usual care alone, leaving limited evidence on cost-effectiveness and on whether combining interventions produces synergistic, additive, or antagonistic effects. Therefore, it is important to assess the most effective and efficient strategy in the local context.
A successful FIT programme requires adherence to follow-up colonoscopy after an abnormal result. Large studies using data from community or national screening programs have shown colonoscopy completion rates of only 32%-56% within 1 year of an abnormal FIT/FOBT, and non-adherence to follow-up colonoscopy is associated with higher CRC incidence and mortality. A meta-analysis of 21 studies by our study team identified four interventions that increased completion of follow-up colonoscopy after an abnormal FIT: patient navigation (RR 1.24), patient reminders (RR 1.32), provider reminders (RR 1.36), and automated referral to gastrointestinal (GI) consult (RR 1.68).
Therefore, this study aims to identify the most effective and cost-effective strategy for increasing CRC screening participation and adherence within Singapore's public healthcare system. Specific objectives are to:
This is a 3-year longitudinal screening trial consisting of 3 annual rounds of screening. Participants enrolled in Round 1 (Year 1) are intended to be followed for subsequent annual screenings (Year 2 and Year 3). Research funding and institutional approval are secured for Round 1; Rounds 2 and 3 are pending final funding approval.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CRC screenings are recommended opportunistically by primary care providers during routine healthcare visits.
Three SMS reminders spaced one week apart will be sent to the patient on top of usual care.
Behavioral: SMS Reminders
Three SMS reminders spaced one week apart will be sent to the patient on top of usual care. A mailed reminder will be sent to participants by the 4th week from Day 0.
Behavioral: SMS reminders + mailed reminder
Three SMS reminders spaced one week apart will be sent to the patient on top of usual care. A mailed reminder will be sent to participants by the 4th week from Day 0. Patient navigation/Follow-up phone call by staff if the FIT kit is not returned by the end of 6th week from Day 0.
Behavioral: SMS reminders + mailed reminder + patient navigation
Three SMS reminders spaced one week apart will be sent to the patient on top of usual care. Participants will be given an option to return the clinic-distributed FIT kits via mail.
Behavioral: SMS reminders + mailed return
A FIT kit will be mailed to the participant's address at the start of the study, accompanied by outreach materials. Three SMS reminders spaced one week apart will be sent to the patient on top of usual care.
Behavioral: SMS reminders + mailed FIT
A FIT kit will be mailed to the participant's address at the start of the study, accompanied by outreach materials. Three SMS reminders spaced one week apart will be sent to the patient on top of usual care. Patient navigation/Follow-up phone call by staff if the FIT kit is not returned by the end of 6th week from Day 0.
Behavioral: SMS reminders + mailed FIT + patient navigation
5,000 patients will be allocated in this arm.
5,000 patients will be allocated in this arm.
5,000 patients will be allocated in this arm.
5,000 patients will be allocated in this arm.
5,000 patients will be allocated in this arm.
5,000 patients will be allocated in this arm.
FIT completion.
By the end of 3 months, FIT completion rates will be analyzed as either completed or not completed.
Time frame: 3 months.
Follow-up Colonoscopy completion after positive FIT screening.
By the end of 6 months after positive FIT, follow-up Colonoscopy rates will be analyzed as either completed or not completed.
Time frame: 6 months after positive FIT screening.
Diagnosis of CRC.
Diagnosis of CRC will be ascertained by histology obtained from colonoscopy. Diagnosis of CRC will be analyzed as either positive for CRC or normal.
Time frame: 6 months.
Stage of CRC at diagnosis.
Our study will collect the stage of CRC at diagnosis. Staging will be determined by the AJCC 8th Edition TNM Staging System for CRC.
Time frame: 6 months.
Cancer-specific mortality.
Our study will collect data on cancer-specific mortality till end of study duration. Patients with cancer-related causes of mortality will be analyzed as cancer-specific mortality.
Time frame: 4 years.
Cost-effectiveness of the screening programme.
Combination of costs incurred from intervention delivery, implementation, navigation, and downstream healthcare costs. Cost-effectiveness analysis will be conducted using a Markov modelling approach, with health states corresponding to different stages of disease including disease-free, different stages of CRC, remission, and death.
Time frame: 4 years post-randomization.
Plan to share: Undecided
Start is estimated for Oct 2026; primary completion for Oct 2029, 36 months later.
Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 36 months is above that.
Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Centre, Singapore →